See feature articles below:
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
OGXI Report
A number of investment brokers have recently updated their price targets on shares of OncoGenex Pharmaceuticals Inc. (OGXI).
Most recent broker ratings
01/22/2016 – OncoGenex Pharmaceuticals Inc. had its “buy” rating reiterated by analysts at Needham & Company. They now have a USD 3 price target on the stock.
01/21/2016 – OncoGenex Pharmaceuticals Inc. had its “sector perform” rating reiterated by analysts at RBC Capital. They now have a USD 1 price target on the stock.
12/02/2015 – OncoGenex Pharmaceuticals Inc. was downgraded to “hold” by analysts at Stifel Nicolaus.
09/24/2015 – OncoGenex Pharmaceuticals Inc. had its “outperform” rating reiterated by analysts at William Blair. They now have a USD 6 price target on the stock.
The share price of OncoGenex Pharmaceuticals Inc. (OGXI) was up +10.26% during the last day of trading, with a day high of 0.88. 244166 shares were traded during the last session.
The stock’s 50 day moving average is 0.77 and its 200 day moving average is 1.26. The stock’s market capitalization is 25.63M. OncoGenex Pharmaceuticals Inc. has a 52-week low of 0.46 and a 52-week high of 4.10.
OncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company’s product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell’s adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5).
Current drug pipeline and progress- http://ir.oncogenex.com/#
Source- RisersandFallers, http://ir.oncogenex.com/#, stockcharts.com
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.
